|From: NetworkNewsWire (Rep: 0)||Date: 01/08/2018 18:28|
|Forum: Penny Stocks - Msg #1141 - List LXRP msgs ||Thread #673980508 (Rec: 0) |
|NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Recaps 2017 Highlights|
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced the release of a 2017 year-end summary penned by CEO Chris Bunka. The release highlights what Bunka refers to as Lexaria’s “busiest and most productive” year to date, including details about the company’s progress toward strengthening its balance sheet, ongoing research and development efforts related to its patented DehydraTECH™ absorption and palatability enhancing technology, its preparations for increased demand in both Californian and Canadian markets and its ongoing efforts to strengthen its intellectual property portfolio. Bunka concludes the review by looking ahead to Lexaria’s plans for 2018, including efforts to utilize its patented technology to produce increased corporate revenues.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.